Trial Profile

A First-In-Human Phase I, Open-Label, Dose-Escalating Trial to Assess the Safety, Tolerability and Immunogenicity/Preliminary Antitumor Activity of ES2B-C001 With or Without [Adjuvant] in HER2 Expressing Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ES2B C001 (Primary) ; Montanide ISA-51 (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions; First in man
Sponsors ExpreS2ion Biotechnologies

13 Apr 2026 Planned number of patients changed from 27 to 40.
13 Apr 2026 Planned End Date changed from 1 Mar 2026 to 1 Dec 2026.
13 Apr 2026 Planned primary completion date changed from 1 Mar 2026 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com